Initiation of Phase 2b Trial for Novel AML Consolidation Treatment with BL8040

BioLineRx Announces Initiation of Phase 2b Trial for Novel AML Consolidation Treatment  Phase 2b study, as consolidation treatment for AML patients responding to standard induction treatment, will enroll up to 194 patients, randomized in 1:1 ratio, at up to 25 sites in Germany